Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology - Tập 24 - Trang vi39-vi50 - 2013
Michael J. Seckl1, Neil J. Sebire2, Rosemary A. Fisher1, François Golfier3, Leon Massuger4, Cristiana Sessa5
1Department of Cancer Medicine
2Department of Histopathology, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, London, UK
3Centre de Référence des Maladie Trophoblastiques, Hospices Civils de Lyon, Lyon, France
4Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
5Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Tóm tắt

Từ khóa


Tài liệu tham khảo

Seckl, 2010, Gestational trophoblastic disease, Lancet, 376, 717, 10.1016/S0140-6736(10)60280-2

Schmid, 2009, Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study, Lancet, 374, 48, 10.1016/S0140-6736(09)60618-8

Hou, 2008, Changes of clinical features in hydatidiform mole: analysis of 113 cases, J Reprod Med, 53, 629

Fowler, 2007, Histomorphometric features of hydatidiform moles in early pregnancy: relationship to detectability by ultrasound examination, Ultrasound Obstet Gynecol, 29, 76, 10.1002/uog.3880

Hinshaw, 2006, The management of early pregnancy loss

Seckl, 2004, Routine terminations of pregnancy-should we screen for gestational trophoblastic neoplasia, Lancet, 364, 705, 10.1016/S0140-6736(04)16898-0

Fisher, 2011, What a difference an egg makes, Lancet, 378, 1974, 10.1016/S0140-6736(11)61751-0

Sebire, 2002, Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin, Lancet, 359, 2165, 10.1016/S0140-6736(02)09085-2

Fisher, 2007, The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies, Gynecol Oncol, 107, 413, 10.1016/j.ygyno.2007.07.081

Sebire, 2010, Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions, J Reprod Med, 55, 236

Sebire, 2013, Histopathological features of biparental complete hydatidiform moles in women with NLRP7 mutations, Placenta, 34, 50, 10.1016/j.placenta.2012.11.005

Shih, 1998, Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma, Am J Surg Pathol, 22, 1393, 10.1097/00000478-199811000-00010

Sebire, 2007, Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit, BJOG, 114, 760, 10.1111/j.1471-0528.2007.01320.x

Kohorn, 2002, Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report, J Reprod Med, 47, 445

Agarwal, 2012, Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study, Lancet, 379, 130, 10.1016/S0140-6736(11)61265-8

Agarwal, 2012, Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia, Br J Cancer, 106, 1089, 10.1038/bjc.2012.65

Berkowitz, 2009, Current management of gestational trophoblastic diseases, Gynecol Oncol, 112, 654, 10.1016/j.ygyno.2008.09.005

Darby, 2009, Does chest CT matter in the staging of GTN?, Gynecol Oncol, 112, 155, 10.1016/j.ygyno.2008.10.003

FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. International Journal of Gynecology & Obstetrics 77:285-287.

Alazzam, 2009, First line chemotherapy in low risk gestational trophoblastic neoplasia, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD007102.pub2

Kohorn, 2002, Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance?, Gynecol Oncol, 85, 36, 10.1006/gyno.2001.6533

Osborne, 2011, Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study, J Clin Oncol, 29, 825, 10.1200/JCO.2010.30.4386

Lurain, 2012, Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia, J Reprod Med, 57, 283

McNeish, 2002, Low risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid, 1992 to 2000, J Clin Oncol, 20, 1838, 10.1200/JCO.2002.07.166

Sita-Lumsden, 2012, Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009, Br J Cancer, 107, 1810, 10.1038/bjc.2012.462

Lybol, 2012, Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia, Gynecol Oncol, 125, 576, 10.1016/j.ygyno.2012.03.003

McGrath, 2010, The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1), Br J Cancer, 102, 810, 10.1038/sj.bjc.6605529

van Trommel, 2006, Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease, J Clin Oncol, 24, 52, 10.1200/JCO.2005.03.3043

You, 2013, Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements, Br J Cancer, 108, 1810, 10.1038/bjc.2013.123

Deng, 2009, Combination chemotherapy for high-risk gestational trophoblastic tumour, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD005196.pub3

Kim, 1998, Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT—25 years experiences of KRI-TRD, Int J Gynaecol Obstet, 60, S85, 10.1016/S0020-7292(98)80010-6

Bower, 1997, EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, J Clin Oncol, 15, 2636, 10.1200/JCO.1997.15.7.2636

Turan, 2006, Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia, Int J Gynecol Cancer, 16, 1432, 10.1136/ijgc-00009577-200605000-00074

Newlands, 2002, Management of brain metastases in patients with high-risk gestational trophoblastic tumors, J Reprod Med, 47, 465

Ahamed, 2012, Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving?, J Reprod Med, 57, 262

Alifrangis, 2013, EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis, J Clin Oncol, 31, 280, 10.1200/JCO.2012.43.1817

Seckl, 2009, Investigation and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours/neoplasia in the United Kingdom, 335

Lybol, 2012, Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy, Ann Oncol, 23, 2903, 10.1093/annonc/mds199

Dhillon, 2006, Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia, J Reprod Med, 51, 879

Lurain, 2005, Secondary chemotherapy for high-risk gestational trophoblastic neoplasia, Gynecol Oncol, 97, 618, 10.1016/j.ygyno.2005.02.004

Newlands, 2000, J Clin Oncol, 18, 854, 10.1200/JCO.2000.18.4.854

Jones, 1996, Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases, Gynecol Oncol, 61, 126, 10.1006/gyno.1996.0110

Osborne, 2004, Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet, J Reprod Med, 49, 655

Termrungruanglert, 1996, Remission of refractory gestational trophoblastic disease with high-dose paclitaxel, Anticancer Drugs, 7, 503, 10.1097/00001813-199607000-00001

Wang, 2008, Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE), Ann Oncol, 19, 1578, 10.1093/annonc/mdn181

Pandian, 2004, Gestational choriocarcinoma: an unusual presentation with response to gemcitabine and surgery, BJOG, 111, 382, 10.1111/j.1471-0528.2004.00065x.x

Bianconi, 2007, Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine, Gynecol Oncol, 106, 268, 10.1016/j.ygyno.2007.04.002

El-Helw, 2005, High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia, Br J Cancer, 93, 620, 10.1038/sj.bjc.6602771

Palmieri, 2005, Placental site trophoblastic tumour arising from a partial hydatidiform mole, Lancet, 366, 688, 10.1016/S0140-6736(05)67143-7

Cole, 2006, Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free beta-subunit, a reliable marker of placental site trophoblastic tumors, Gynecol Oncol, 102, 160, 10.1016/j.ygyno.2005.12.046

Harvey, 2008, Human chorionic gonadotropin free beta-subunit measurement as a marker of placental site trophoblastic tumors, J Reprod Med, 53, 643

Pfeffer, 2007, Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour, Lancet Oncol, 8, 744, 10.1016/S1470-2045(07)70243-7

The ISSTD global Placental Site Trophoblastic Tumour database. International Society of the Study of Trophoblastic Diseases. https://pstt.shef.ac.uk.

Rustin, 1996, Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumours increases the incidence of second tumours, J Clin Oncol, 14, 2769, 10.1200/JCO.1996.14.10.2769